The Week Ahead in Life Sciences

Research evidence excerpt

The Week Ahead in Life Sciences

(a weekly publication detailing key catalysts in our coverage universe)

June 18, 2026

(dollars in millions)

Events Highlighted in the Coming Month

Company/Event Ticker Rating Mkt cap Timing Anticipated Event

Biogen BIIB Neutral $29,331 2Q26 Potential Phase 2 results of BIIB091 (peripheral BTKi in MS)

Larimar Therapeutics LRMR Outperform $368 2Q26 Report open-label study data supporting BLA for nomlabofusp in Friedreich’s Ataxia (FA)

Bicara Therapeutics BCAX Outperform $1,506 2Q26 Long-term follow up data from Ph 1b study of ficerafusp alfa + pembrolizumab in HPV-negative 1L R/M HNSCC

TScan Therapeutics TCRX Outperform $59 2Q26 Initial results from Cohort C of ALLOHA (commercial-ready manufacturing process)

MoonLake Immunotherapeutics MLTX Outperform $1,413 2Q26 52-week data from the Phase 3 VELA-1 and VELA-2 studies of sonelokimab in hidradenitis suppurativa (HS)

MoonLake Immunotherapeutics MLTX Outperform $1,413 2Q26 Top-line data from the Phase 3 VELA-TEEN study of sonelokimab in adolescent patients with hidradenitis suppurativa (HS)

Opus Genetics IRD Outperform $330 2Q26 Top-line data from the second Phase 3 study of phentolamine ophthalmic solution 0.75% in night vision disturbances

Protagonist Therapeutics PTGX Outperform $7,167 2Q26 Top-line data from the Phase 3 study of icotrokinra in patients with psoriatic arthritis (PsA) that are biologic naïve

Source: Wedbush Securities, Inc.

Wedbush Healthcare Coverage (Part 1 of 9)

Gossamer Bio GOSS Neutral $88 Mid-June FDA Type B Meeting for seralutinib registrational path in PAH

Viridian Therapeutics VRDN Outperform $1,845 June 30, 2026 PDUFA date for veligrotug in TED